Market Data 
Ulta Beauty’s CEO said weight loss drugs are sending customers to pick up new beauty products.
“Hair loss with GLP-1s is real, and products that can help with that,” Kecia Steelman said in an interview with Yahoo Finance’s Opening Bid, released on Monday. “And then also skin elasticity, when you’re losing weight really rapidly, you know, the skin elasticity is something that you’ve got to get moisture into.”
She said there was a crossover in the types of products sought by GLP-1 users and people with aging skin. Both groups are trying to find products that are helping maintain “the longevity of the look.”
GLP-1 drugs are seeing a massive rise in popularity in the US. An EY consumer products expert told Business Insider in 2025 that 10% of the country’s population is on some sort of weight-loss drug.
An Ulta Beauty representative did not respond to a request for comment from Business Insider about which specific products are seeing an increase in demand because of the weight-loss trend.
Hair loss is a side effect of GLP-1 drugs, sold under brand names like Ozempic and Wegovy. It was reported as a side effect in 3% of people in Wegovy clinical trials.
Other companies are cashing in on the “Ozempic face” phenomenon.
The CEO of Swiss pharmaceutical giant Galderma told Bloomberg in 2024 that he sees a strong demand for facial fillers to counteract the sunken look that some GLP-1 users develop.
The effects of weight-loss drugs have manifested in many other ways. Tailors on Wall Street told Business Insider in January that their clients have brought back entire wardrobes to be taken in.
Ulta Beauty reported 2025 annual sales of about $12.39 billion, up 11.8% from the year before. Skincare, wellness, and hair care accounted for 43% of its total sales.
The company’s stock price has risen about 50% in the past year.
Read the full article here
